Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Kyowa Hakko Kirin to Develop Expert MRs to Boost Cancer Field
January 11, 2012
-
BUSINESS Bayer Yakuhin President Guth Says Marketing Success of 2 Strategic Products Key Focus
January 10, 2012
-
BUSINESS AZ to Utilize E-detailing, Optimize According to Product
January 6, 2012
-
ORGANIZATION FPMAJ Chairman Pledges Further Efforts for Permanent Introduction of Premium, Caution Towards Additional Price Cuts Becoming Rule
January 5, 2012
-
ORGANIZATION New Year’s Message: On behalf of the JPMA, I would like to express our best wishes for a Happy New Year as we see the start of 2012.
January 5, 2012
-
BUSINESS Aricept Overtakes Blopress to Take Top Spot in Domestic Drug Sales
December 28, 2011
-
REGULATORY Additional NHI Price Cuts Decided: ¥22.5 Billion for Long-Listed Drugs, ¥2.5 Billion for Generics
December 27, 2011
-
REGULATORY PFSB Draft Budget Includes ¥2.1 Bil. to Improve Review, Safety Measures
December 27, 2011
-
BUSINESS Chugai to Participate in Multinational Study of Avastin in Breast Cancer
December 27, 2011
-
REGULATORY Tougher Restrictions on Reimbursement of Vitamins to Cut ¥15 Bil. from Med. Expenditure
December 26, 2011
-
REGULATORY ¥25 Bil. to Be Saved through Add’l NHI Price Cuts for Both Long-listed, Generic Drugs in FY2012: MHLW
December 26, 2011
-
REGULATORY 0.9% Additional Price Cut for Long-Listed Drugs, Compensating Upward Revision of Nursing Fee: Minister Negotiation
December 22, 2011
-
BUSINESS Ranbaxy Settles with US FDA, Commits to Improvements in GMP Compliance, Data Integrity: Daiichi Sankyo
December 22, 2011
-
REGULATORY CSIMC Approves Additional Price Reduction for Long-listed Drugs Next Year
December 22, 2011
-
REGULATORY Price Cut Negotiations for Long-Listed Products Between MOF, Health Ministers “Parallel”
December 21, 2011
-
BUSINESS MTPC, Novartis Pharma Focused on Promoting Proper Use of MS Treatment Imusera/Gilenya
December 21, 2011
-
BUSINESS Chugai to Establish Pool System of Candidate Leaders
December 20, 2011
-
ORGANIZATION Mr Sawai of JGA Announces “Absolute Opposition” to Add’l Price Reduction for Generics
December 20, 2011
-
REGULATORY MHLW Subcommittee Agrees on Mandatory Notification of Package Inserts
December 19, 2011
-
REGULATORY Expert Subcommittee Agrees to 2-Year Continuation of Trial of Premium for New Drug Development
December 19, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…